Oct
12
2022
On demand
Predicting patient response to immune targeted therapies via interrogation of the TME
Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
More accurately predicting which patients will benefit from immune targeted therapies, including checkpoint inhibitors, remains a crucial goal for the I–O field.
This webinar will provide an overview of an RNA-based investigational tumor microenvironment (TME) panel to better interrogate tumor biology and support multiple oncology therapeutics – particularly immune checkpoint inhibitors and anti-angiogenic agents – across a range of tumor types.
New translational data on predicting benefit from maintenance durvalumab after first-line chemotherapy in esophagogastric adenocarcinoma will be discussed, along with the potential for companion diagnostic development in support of clinical development.
- The broad clinical and research applications of an RNA-based TME assay for I–O applications
- How interrogation of the TME via RNA signatures can improve the identification of patients who might benefit from multiple oncology therapeutics, particularly immune checkpoint inhibitors and anti-angiogenic agents
- Future development of the Xerna TME Panel as an RUO, CTA and CDx assay platform
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Emily Neil, Ariadna Pascual
27 June
in 69
Days
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Adam Crowe
29 May
in 40
Days
Empowering patient care: in-process and quality control solutions for cellular therapies
Christin Tischner, Simon Lennartz
23 May
in 34
Days
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Meredith Safford, ShaNelle Yelity
22 May
in 33
Days
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time
Emily Jackson-Holmes
21 May
in 32
Days